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During the last few years, stem cell technology has elicited
a great deal of fascination, hope and controversy as have
done other cell research programs. The primary aim of
developing stem cells for medical application is to
regenerate tissues and repair failing organs. In addition,
stem cell research can be viewed as a key to addressing and
understanding many of the most fundamental and basic
questions in clinical biology. A better insight into early cell
development will provide answers to the question why cells
behave abnormally and generate pathologies such as cancer
or autoimmune and degenerative diseases. The huge interest
focussing on this research and its potentially therapeutic
applications are evident from the large investment made by
companies, governments and universities worldwide.
In October and November 2010, the two first human
trials of cell therapy by embryonic stem cell-derived
injections for spinal cord injury and non-hereditary forms
of blindness were approved by the FDA. The source of
stem cells, however, remains a subject of debate. Taking
into account genetic and immunological criteria, stem cells
can be derived from either of the following:
1. An individual that is genetically unrelated to the recipient.
This applies to cells like embryonic stem cells.
2. Adult cells that have been reprogrammed to induce
pluripotent stem cells (iPS). The advantage of iPS is
that they are derived from adult tissues, thus obviating
the use of embryos. The origin of the adult tissue to
prepare iPS can theoretically be the patient itself,
leading to the situation of autologous transplantation.
Unfortunately, this is offset by some drawbacks that,
for the time being, preclude their use in procedures of
human stem cell therapy. The use of transduction
vectors like retroviruses could be associated with
insertional mutagenesis and the insertion of pluripotent
genes like the oncogene MIC could theoretically be
linked to tumorigenesis. Also, from a practical point of
view, the preparation of iPS of a clinical grade suitable
for transplantation in patients could be difficult to
achieve for reasons of time and cost effectiveness.
Different methods will have to be set up, leading to
homogeneous and reproducible cell populations that
do not form teratoma or other cancers. Therefore, the
use of stem cells derived from embryos or the
creation of banks of stem cells generated in good
manufacturing practice laboratories would signify a
genetic mismatch between donor’s and recipient’s
cells and serious problem of transplant rejection by
the immune system. Despite the potential of human
embryonic stem (ES) cells, important issues sur-
rounding immunogenicity subsist, and strategies to
avoid rejection remain largely untested. In addition,
even if iPS derived from the patients would consti-
tute eventually a perfect immunological match, the
risk of rejection by inflammation and by the innate
immune system activated by the transplantation
procedure must not be taken lightly.
The special reviews issued by the Seminars in
Immunopathology are intended to summarize current
knowledge on immunological problems with regards to
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the transplantation of stem cells or their progenitors. In the
first review, obtaining stem cells for regenerative medicine
is extensively discussed by Olivier Preynat-Seauve and
Karl-Heinz Krause. Several types of stem cells have been
identified and isolated from embryos, foetus or adult
organs, and each distinct type of stem cells harbors
different properties, providing multiple strategies, while
immunological considerations associated with their use are
highlighted. Casmir de Rham and J. Villard summarize the
genetic and immunological barriers to human ES cell
transplantation. These are: blood groups, MHC and minor
antigens that have to be crossed for a successful transplanta-
tion. One of the principal difficulties in cell and tissue
transplantation is the implantation step. Engraftment and
persistency of cells are impeded by several adverse processes
like apoptosis, anoikis or necrosis. Ian Copland and Jacques
Galipeau review these crucial difficulties, taking as an
example mesenchymal stem cells (MSC) that are currently
used in clinical trials for different disorders ranging from heart
disease to graft-versus-host disease in pediatric patients. This
is, as far as we know, one of the first reviews on this critical
topic. The potential use of MSC for tissue repair and
immunotherapy has been clearly demonstrated during the
past decade. MSC can exhibit immunomodulatory functions
that could be beneficial for cell therapy. Ilaria Marigo and
Francesco Dazzi have contributed a state of-the-art review on
this important topic.
Immunogenicity of undifferentiated pluripotent stem
cells could be different from the lineage derived from
them. Susan Kadereit reviews this highly important aspect
of stem cell biology. Philippe Capetian, Maté Döbrössy,
Christian Winkler, Marco Prinz and Guido Nikkhah point
out the implications of grafting neural stem cells into the
central nervous system. The procedure has been performed
in several animal models and also in a limited number of
small human clinical studies. The authors relate their
experiments with allograft cells in the absence of immuno-
suppressive agents and the role of immunologically
privileged site like CNS as compared to other engraftment
sites in the body. Chad Tang and Micha Drukker focus on a
very interesting topic, that of propagation and non-
physiological differentiation of pluripotent stem cells which
can induce the expression of aberrant antigens. This may
apply to allogenic pluripotent stem cells but also for iPS
with new antigens resulting from long-term maintenance
in vitro.
The article by Senju Satoru, Yusuke Matsunaga, Satoshi
Fukushima, Tokumori Ikeda and Yasuharu Nishimura
assesses the suitability of pluripotent stem cells for
generating dendritic cells (DC) and providing an unlimited
source of DC for potential use in anti-cancer vaccine
therapy. The authors describe methods of differentiation
into functional DC from pluripotent stem cells of mice and
human origins. Nicholas Zavazava reviews the use of
human ES cells to generate an alternative source of
hematopoietic stem cells for possible use in cell therapy
in medical conditions including hematopoietic stem cell
malignancies, immunodeficiency and autoimmune diseases.
He discusses the immunological properties of ES derived
from hematopoietic progenitors and from other tissue.
One major problem encountered in the clinical application
of stem cells is the risk of tumor formation. Ralf Dressel
highlights recent data on the tumorigenicity of pluripotent
stem cells in autologous, allogenic and xenogenic immuno-
deficient hosts. The effect of immunosuppresive treatment on
tumor development is also discussed. Finally, Outi Hovatta
examines the critical issue of clinical applications of stem cells
and their linage. Stem cells have to be cultured according to
good manufacturing practice and a quality control system to
minimize the risks. The screening of donor cells for human
pathogens, the selection of xeno-free chemicals and meticu-
lously validated laboratory procedures are crucial steps to
implement and prove the procedure’s safety.
Undoubtedly, stem cells research will continue to offer
tremendous promise along with the possibility of generat-
ing products that could revolutionize the treatment of
disease and the regeneration of damaged tissues. This
optimistic outlook needs, however, to be tempered owing to
the plethora of ethical, legal, political and financial
challenges that face this research. Some of these are
certainly of an immunological nature and will have to be
taken into account and solved, at least in part, to guarantee
the success of human stem cell therapy. Meetings that
provide the opportunity for interaction between scientists
involved in stem cell research and those active in transplant
immunology are ideal for considering and finding solutions
to the serious issue represented by the rejection of the
transplanted tissues. We hope that the current issue of the
Seminars in Immunopathology will contribute to the joining
of forces between basic scientists and clinicians with a view
to obtain the best possible results in stem cell research for
clinical application.
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